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Abstract 
Pseudomyogenic hemangioendothelioma is a rare, recently described neoplasm that usually pre- 
sents as multifocal lesions in a single extremity. The disease has demonstrated a high propensity 
for infiltrative growth and local recurrence but limited metastatic potential. Variations of histo-
logical appearance and immunohistochemical signatures have been described, but typically in-
volve spindle or polygonal cells with nuclear atypia and neutrophilic infiltration. Here we present 
a case report of an 8-year-old female who presented with hip pain that was initially diagnosed and 
managed as a slipped capital femoral epiphysis (SCFE). Subsequent evaluation led to the diagnosis 
of pseudomyogenic hemangioendothelioma of bone. Due to the degree of osseous destruction, de-
scribed patterns of local recurrence, and metastatic potential of this neoplasm, a wide resection 
with endoprosthetic reconstruction of the proximal femur was performed. This case highlights the 
importance of due diligence in the diagnoses of SCFE and bone tumors in young patients with ab-
normalities of the proximal femur, including consideration of the need for biopsy. 
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1. Introduction 
Pseudomyogenic hemangioendothelioma is a recently described neoplasm that most often presents as multifocal 
lesions in one extremity. Over the last several years, additional descriptions of this disease have emerged, with 
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characterization of its clinical, ultrastructural, and histological components [1]-[9]. This disease is poorly un-
derstood, diagnosis is challenging, and optimal management is uncertain. This rare tumor features locally ag-
gressive behavior and high probability of recurrence but low metastatic potential. In this report, we describe a 
unique case of pseudomyogenic hemangioendothelioma that was first diagnosed as a slipped capital femoral 
epiphysis (SCFE) and only later appropriately diagnosed and managed. 
2. Case Presentation 
The patient is an eight year six month female who presented to a tertiary pediatric orthopaedic practice with a 
chief complaint of right hip pain for approximately one month after sustaining a fall. Prior to the fall she had 
been previously healthy and reported no antecedent right hip pain or any other medical problems. She was di-
agnosed with a slipped capital femoral epiphysis (SCFE) (Figure 1) and was admitted to the hospital for percu-
taneous screw fixation, which proceeded without complication. During her post-operative period, she was com-
pliant with non-weight bearing instructions and her pain subsided. However, subsequent radiographs at 2 
months post-operative showed infiltrative lucency, osseous destruction, and irregularity of the femoral head and 
neck (Figure 2). Endocrinologic and hematologic evaluations were negative. An infectious evaluation was per-
formed and found to be negative. MRI and CT evaluation were non-diagnostic (Figure 3 and Figure 4), and she 
underwent CT-guided biopsy that was likewise inconclusive. 
 
 
Figure 1. AP radiograph of the patient’s pelvis at the time of 
her initial presentation. Her right capital femoral epiphysis is 
certainly widened, but the femoral neck and head have an ab-
normal, infiltrative appearance compared with the left side. 
 
 
Figure 2. Shows the patient’s frog-lateral radiograph subse-
quent to screw fixation. The bone is clearly abnormal on this 
image. 
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Figure 3. 3-D CT scan of the patients right hip suggesting an 
infiltrative process in the femoral neck and head. 
 
 
Figure 4. Displays an axial CT scan image, which demon-
strates a lobular, infiltrative, lucent pattern within the femoral 
neck and head. The proximal femur was ultimately determined 
to be un-salvageable. 
 
She was then referred to a musculoskeletal oncology service. Due to the non-diagnostic nature of her prior 
evaluations, she was taken to the operating room for an open biopsy through a lateral approach. Histologic 
evaluation showed foci of single and clustered epithelioid cells embedded within a fibrous stroma in the inter-
trabecular spaces. Reticulin stain demonstrated that most clustered cells were within vascular-type spaces. The 
cells immunostained variably for CD31 and cytokeratin AE1/AE3, with faint immunopositivity for smooth 
muscle actin (Figure 5 and Figure 6). 
She was taken to the operating room and a wide resection (Figure 7) and endoprosthetic reconstruction were 
performed with negative histologic margins (Figure 8). There were no complications, and the patient progressed 
her weight bearing over several months post-operatively. The patient is currently 9 months post-operative and 
fully weight-bearing without pain or complaints. There is no clinical or radiographic evidence of recurrent dis-
ease. 
3. Discussion 
Pseudomyogenic hemangioendothelioma is rare, recently recognized disease entity. While the terminology 
“pseudomyogenic hemangioendothelioma” has only lately been established, multiple case series have reported 
on a constellation of clinical, morphological, and histological findings that likely describe similar disease entities  
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Figure 5. Shows a histological slide of the re-
sected tumor (H & E). Note the plump epithelio-
id-like cells growing in fascicles and invading 
the bone. 
 
     
Figure 6. Immunohistochemistry pathology slides demonstrating (left) variable cytokeratin AE1/ 
AE3 staining (middle) reticulin stain demonstrating cell clustering within vascular-type spaces (right) 
variable CD31 staining. 
 
 
Figure 7. Presents the patient’s bisected gross 
specimen. The lobular, abnormal tumor bone (pink) 
is in sharp contradistinction to the normal bone 
(brown). 
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Figure 8. Display the patient’s post-operative (left) AP pelvis and (right) AP hip views, respec-
tively. A compressive osseointegration prosthesis was chosen to maximize the advantages of 
wide resection and biologic fixation. 
 
[1]-[3]. Despite the multiple names associated with this disease process, it is referred to as pseudomyogenic he-
mangioendothelioma in the most recent WHO classification [4]. 
In 1992, Mirra et al. [3] described what the authors called a fibroma-like variant of epithelioid sarcoma in a 
small case series of 5 patients. The clinical presentation, ultrastructural features, and presence of vimentin and 
low molecular weight keratin within the tumor cells justified their designation as an epithelioid sarcoma variant. 
However, the tumors were unique morphologically and the authors categorized them separately. In 2003, Bil-
lings et al. [1] described seven tumors originally described as epitheliod sarcomas, but with distinctive morpho-
logic and immunophenotypic features. Based upon further histologic examination, the cases were labeled epi-
thelioid sarcoma-like hemangioendothelioma. In 2011, Hornick and Fletcher [2] described 50 cases of this dis-
tinctive tumor, describing its clinical presentation, behavior, morphology and immunophenotype. They named 
the tumor pseudomyogenic hemangioendothelioma. It is now generally proposed that these three papers describe 
the same rare neoplasm. 
Microscopically, the neoplastic lesions are composed of plump spindle or polygonal cells, occasionally rhab-
domyoblast-like, with abundant eosinophilic cytoplasm, and more rarely epithelioid cells arranged in ill-defined 
sheets, nodules or fascicles. Nuclear atypia is generally mild to moderate, but is occasionally prominent, and the 
mitotic rate is low with rare necrosis. Prominent infiltration by neutrophils is commonly seen. The lesions typi-
cally show a limited infiltrative growth pattern [5] [6]. Immunohistochemistry shows expression of cytokeratin 
AE1/AE3, FLI-1 and ERG, as well as expression of CD31 in half of all cases [1] [5]. Recently, a novel translo-
cation, t(7;19) (q22;q13), has been identified for pseudomyogenic hemangioendothelioma [9]. 
Pseudomyogenic hemangioendothelioma classically affects young adults, rarely over the age of 40, with a 
strong male predominance. Tumors usually involve the extremities and are multicentric, involving multiple tis-
sues planes, from dermal, subcutaneous, subfascial, and importantly, osseous. Previous case series suggest an 
indolent course for this type of tumor [1] [2]. Tumors are treated with local excision/resection in most cases, 
even when there are multiple lesions. Local recurrence is common. Extensive multifocal disease in an extremity 
may necessitate amputation; the literature describes both transfemoral and transtibial amputations as well as a 
hip disarticulation. In review of the pseudomyogenic hemangioendothelioma literature, only three patients have 
developed distant metastases; one during the initial evaluation and the other two which occurred several years 
following excision/resection of the primary tumors [2] [3] [7]. 
Sheng and Wang [8] describe a unique case of pseudomyogenic hemangioendothelioma presenting as multi-
focal disease in the long bones of a 10-year-old girl. Lesions in her distal tibia and fibula as well as the distal 
femur were curetted and filled with bone cement; the distal femur lesion recurred with extension into the soft 
tissues. Further, this patient also developed a lesion of the proximal tibia several years later. The authors de-
scribe this multifocal disease as the first case of primary pseudomyogenic hemangioendothelioma of bone. 
Pseudomyogenic hemangioendothelioma of bone is a rare tumor and the literature is not replete with guidance 
on how to optimally manage this disease. While the disease appears to have a limited metastatic potential, it has 
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a high propensity for infiltrative growth and local recurrence. Given the local aggression and seemingly large 
area of disease in the proximal femur in the patient described in this case report, wide resection with endopros-
thetic reconstruction was performed to minimize local recurrence. Especially due to the patient’s young age, im-
plant choice was challenging, but ultimately a proximal femoral replacement with compressive osseointegration 
was chosen to allow for biologic ingrowth while minimizing bony resection. 
This case also highlights the importance of due diligence in the diagnosis of SCFE in a young patient with 
osteolytic abnormalities of the proximal femur as well as close radiographic follow-up in the post-operative pe-
riod following screw fixation. An appropriate work-up was obtained to investigate her abnormality further and a 
broad differential diagnosis was entertained. Ultimately, the histological specimen was diagnostic. Further, al-
though the first CT-guided biopsy was inconclusive, high clinical suspicion led to an open biopsy of the lesion, 
which led to the definitive diagnosis and treatment. Clearly, additional clinical and basic scientific research is 
required before a consensus on the appropriate treatment of this rare tumor is rendered. 
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